DNA甲基化与精神分裂症和重性抑郁障碍中相反的NMDAR功能障碍:致幻化合物治疗精神疾病疗效的汇聚模型
本文综述提出DNA甲基化改变是致幻化合物治疗精神分裂症(SZ)和重性抑郁障碍(MDD)疗效的汇聚模型,并以NMDAR为锚定点。文章回顾了DNA甲基化异常与两种疾病中NMDAR功能障碍相关的既定证据,并提出致幻物质可能通过表观遗传机制发挥治疗作用。
要点
- DNA甲基化作为表观遗传调控参与SZ和MDD的病理生理。
- NMDAR在两种疾病中均存在功能障碍,被视为汇聚锚定点。
- 致幻化合物可能通过表观遗传机制发挥治疗效应。
核心结论
- DNA甲基化改变可能是致幻化合物治疗精神分裂症和重性抑郁障碍疗效的汇聚机制,并以NMDAR功能障碍为锚定点。
研究设计与样本
- 本文为综述,回顾了DNA甲基化与NMDAR功能障碍在精神分裂症和重性抑郁障碍中的既定证据。
主要发现
- DNA甲基化异常与精神分裂症和重性抑郁障碍的病理生理相关。
- NMDAR作为突触可塑性的关键介质,在两种疾病中均存在已知功能障碍。
- 致幻物质可能通过表观遗传机制在两种疾病背景下产生治疗效应。
临床怎么用
- 该模型提示致幻化合物的治疗效应可能通过表观遗传调控NMDAR功能实现,为精神疾病治疗提供机制假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychedelic compounds are being increasingly explored as a potential therapeutic option for treating several psychiatric conditions, despite relatively little being known about their mechanism of action. One such possible mechanism, DNA methylation, is a process of epigenetic regulation that changes gene expression via chemical modification of nitrogenous bases. DNA methylation has been implicated in the pathophysiology of several psychiatric conditions, including schizophrenia (SZ) and major depressive disorder (MDD). In this review, we propose alterations to DNA methylation as a converging model for the therapeutic effects of psychedelic compounds, highlighting the N-methyl D-aspartate receptor (NMDAR), a crucial mediator of synaptic plasticity with known dysfunction in both diseases, as an example and anchoring point. We review the established evidence relating aberrant DNA methylation to NMDAR dysfunction in SZ and MDD and provide a model asserting that psychedelic substances may act through an epigenetic mechanism to provide therapeutic effects in the context of these disorders.
引用
- Flynn LT, Gao WJ. DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness. Mol Psychiatry. 2023. PMID: 37679470. doi:10.1038/s41380-023-02235-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。